Albert Anthony is the pen name of a Croatian-American media personality on investor platforms Investing.com and Seeking Alpha, where he has grown over +1K followers since 2023 and covers markets & stocks, and as of 2025 hosting an ongoing set of articles called Financial Markets: Growing A Dividend Income Portfolio. His new book of the same name is planned for a 2025 global launch on Amazon soon. A native of the NYC area, he has also called home Austin Texas where he worked as a management & information sys ...

Core Insights - BD has appointed Gregory J. Hayes to its board of directors, effective March 26, 2025, as part of its commitment to strong corporate governance and board refreshment [1][2] - Hayes brings over 30 years of executive experience, including leadership roles in finance, corporate strategy, and business development, and has a proven track record in portfolio optimization and operational efficiency [2][3] - The appointment comes at a crucial time for BD as it plans to separate its Diagnostic Solutions and Biosciences business, aiming to establish 'New BD' as a focused medtech leader [3][4] Company Overview - BD is a leading global medical technology company with a 125-year history, focused on improving medical discovery, diagnostics, and care delivery [4][5] - The company employs over 70,000 individuals and collaborates globally to address significant health challenges, enhancing outcomes and efficiency in healthcare [5] Leadership Background - Gregory J. Hayes previously served as CEO and chairman of United Technologies Corporation, playing a key role in the formation of RTX Corporation through a merger [2][3] - Hayes holds a bachelor's degree in Economics from Purdue University and is a certified public accountant [4]

Core Viewpoint - Becton, Dickinson and Company (BD) has initiated a Class I recall of its infusion pumps due to software issues that could lead to inaccurate therapy administration, posing serious risks to patient safety [1][5]. Group 1: Recall Details - The recall affects the BD Alaris Systems Manager and BD Care Coordination Engine Infusion Adapter, which are critical for the operation of the Alaris infusion pump [2][8]. - The software issues reported include delayed system responses and backlogs of automated programming requests, which may result in incorrect medication doses or infusion rates [5][8]. Group 2: Financial Impact - Following the Class I recall designation, BDX shares have decreased by 0.9%, while the company's shares have gained 0.5% year-to-date compared to the industry’s 1.7% growth [3]. - The relaunch of the Alaris infusion pump in 2023 had previously boosted BD's top line by nearly 50 basis points, indicating potential future sales losses due to the current recall [4]. Group 3: Industry Context - BD is not alone in facing regulatory scrutiny; other companies like Baxter and OptumHealth have also issued recalls due to similar software issues, highlighting a broader industry challenge [9]. - The global infusion pump market, valued at $2.6 billion in 2023, is projected to grow to $3.3 billion by 2033, emphasizing the need for manufacturers to prioritize software integrity [10].

Core Viewpoint - Becton, Dickinson and Company (BDX) is advancing its GalaFLEX LITE Scaffold under an Investigational Device Exemption to secure FDA Premarket Approval, targeting the reduction of capsular contracture recurrence in breast revision surgeries [1][4]. Group 1: Product and Market Context - The GalaFLEX LITE Scaffold is designed to address unmet needs in breast reconstruction, aiming to improve patient recovery, safety, and satisfaction [2]. - Capsular contracture (CC) is a common complication in implant-based breast surgeries, affecting 10% to 20% of patients, leading to pain and potential revision surgeries [6]. - The scaffold is a bioabsorbable surgical mesh made from P4HB, which dissolves over time, supporting tissue integration and reducing mechanical stress during healing [10][11]. Group 2: Clinical Study Details - The pivotal STANCE study will enroll at least 250 patients across 40 sites, comparing the scaffold's effectiveness against standard revision surgery without a supportive matrix [9]. - The study aims to demonstrate the safety and effectiveness of the GalaFLEX LITE Scaffold in improving surgical outcomes [7]. Group 3: Financial and Stock Performance - Following the announcement, BDX shares closed flat at $230.23, with a 2.8% decline over the past six months, while the industry grew by 2.8% [3]. - BDX currently has a market capitalization of $66.11 billion and reported an earnings surprise of 15.1% in the last quarter [5]. - The successful implementation of the GalaFLEX LITE Scaffold could enhance demand from surgeons and hospitals, potentially leading to new revenue streams and improved profitability [4].

Core Insights - BD (Becton, Dickinson and Company) has initiated a clinical trial for the GalaFLEX LITE™ Scaffold aimed at reducing capsular contracture recurrence during breast revision surgery, marking a significant step towards obtaining FDA Premarket Approval [1][3][5] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery, with a commitment to enhancing patient outcomes through innovative technologies [8] Clinical Trial Details - The STANCE study is a multi-center, randomized, controlled trial designed to evaluate the safety and efficacy of the GalaFLEX LITE™ Scaffold in breast implant revision surgery, with an enrollment target of at least 250 patients across 40 sites [5][7] - Capsular contracture is a common complication in implant-based breast surgery, with an incidence rate of 10% to 20%, and conventional surgical techniques have a recurrence risk as high as 54% [2][5] Product Information - The GalaFLEX LITE™ Scaffold is made from Poly-4-Hydroxybutyrate (P4HB), a fully absorbable polymer with over 10 years of clinical use in various surgical applications, designed to provide immediate strength and stability during the wound healing process [3][4] Expert Commentary - Surgeons involved in the trial express optimism about the potential benefits of the GalaFLEX LITE™ Scaffold in improving patient outcomes and addressing a critical complication in breast surgery [4][5]

Core Insights - The Zacks Premium service provides tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales to find attractive investment opportunities [3] - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings and cash flow to identify sustainable growth stocks [4] - The Momentum Score helps investors capitalize on price trends by evaluating recent price changes and earnings estimate shifts to identify high-momentum stocks [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investment strategies [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize potential returns [10] - The direction of earnings estimate revisions is crucial; stocks with lower ranks but high Style Scores may still face downward price pressure [11] Company Spotlight: Becton Dickinson (BDX) - Becton Dickinson, a medical technology company, is currently rated 3 (Hold) with a VGM Score of B, and has shown a 1.4% increase in share price over the past four weeks [12] - Recent upward revisions in earnings estimates by five analysts for fiscal 2025 have raised the Zacks Consensus Estimate to $14.43 per share, with an average earnings surprise of 7.3% [13]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 在医疗科技深度融合临床实践的当下，医学装备行业正经历技术与应用的双重跃迁。从精准诊断到微创治疗，从智能康复到个性化医疗，医学装备的每一次 技术突破都直接影响着医疗质量与患者预后。然而，行业的高速发展不仅带来了创新机遇，也伴随着标准化、适应性落地和成本控制等多重挑战。 在这一背景下， 2025中国医学装备大会暨医学装备展览会 成为观察行业动向的重要窗口。2025年3月13日至16日，重庆国际博览中心将汇聚 800多家企 业 ，展示超过 1000件创新产品 。这不仅是一场技术竞演，更是对医疗装备未来走向的深度探讨——哪些技术能够真正提升临床价值？国产创新如何突破市 场壁垒？政策与产业如何协同推动高质量发展？答案，或将在这次行业盛会上逐步揭晓。 # 会议信息 此次参会的龙头企业包括 强生、雅培、美敦力、直观复星、上海微创机器人、迈瑞医疗、东软医疗、GE医疗、西门子医疗、飞利浦、罗氏、碧迪医疗 等。 34大 专业展区，覆盖了从基础到前沿的每一个细分领 ...

Core Insights - Becton, Dickinson and Company (BD) is actively pursuing a review strategy for its Biosciences division following significant developments in its first quarter report [4]. Group 1: Company Strategy - The company has been heavily investing in technology over the past decade, indicating a long-term commitment to innovation and improvement in its operations [6]. Group 2: Conference Context - The discussion is part of Citi's Unplugged Medtech and Life Sciences Tools Day, highlighting the importance of investor engagement and communication regarding company strategies and performance [1].

FRANKLIN LAKES, N.J., Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences:Citi's 2025 Unplugged Medtech and Life Sciences Access DayFebruary 27, 20258:45 a.m. Eastern TimeBarclays 27th Annual Global Healthcare ConferenceMarch 11, 20258:30 a.m. Eastern TimeThe live webcasts of BD's presentations can be accessed from the BD investor relations website, investors.bd ...

前序文章： 剥离百亿业务，转型医疗器械公司，跨国外企大动作！附PPT全文 # 第一季度财务亮点 # 业务板块表现 近日， 碧迪医疗 （Becton, Dickinson and Company）公布了其 2025财年第一季度 的财务报告结果。 财报显示，碧迪医疗在收入、利润率和每股收益方面均 超出预期，显示出公司在战略转型和业务增长方面的强劲表现。 碧迪医疗董事长、CEO兼总裁 Tom Polen 表示："我们在第一季度实现了强劲的运营表现，收入增长、利润率提升和每股收益均超出预期。我们 通过BD 2025 战略持续转型，并计划分拆生物科学和诊断解决方案业务 ，这将进一步释放价值。我们的团队在执行BD 2025战略和推动业务创新方面表现出色，为未来的 增长奠定了坚实基础。" 股票回购计划：碧迪医疗董事会授权回购高达1000万股普通股，进一步增强了股东价值。 创新与合作：碧迪医疗在多个领域取得了创新进展，包括与Biosero合作加速药物发现和开发，以及推出创新的指尖血检测技术。 市场拓展：碧迪医疗通过增加美国制造网络的产能，满足了对关键医疗设备（如注射器、针头和静脉导管）的持续需求。 眼未来 | 思宇MedTe ...